EYPT

EyePoint, Inc.'s stock price declined significantly by approximately 76.3% to 77.3% over the past six months. A major impact occurred on August 17, 2026, when DURAVYU™ failed to meet the primary endpoint of non-inferiority to aflibercept in the LUGANO Phase 3 clinical trial for wet AMD, causing the stock to fall over 70%. The company attributed this miss to an 'asymmetric cohort' of nine patients experiencing vision loss unrelated to wet AMD. Other events include reporting a net loss of $94.5 million in Q2 2026, missing consensus estimates, and increased operating expenses due to clinical trials and manufacturing scale-up. The company also reported inducement grants on September 16, 2026, and August 14, 2026.